Clinical trial for Recurrent Non-Muscle Invasive Bladder Carcinoma
Official title Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
ClinicalTrials.gov ID: NCT07000084
What this study is testing
What is BCG Solution?
An investigational intravesical therapy being studied for recurrent non‑muscle invasive bladder carcinoma. It is designed to stimulate the immune system by exposing the bladder wall to live BCG bacteria.
Also referred to as Bacillus Calmette‑Guerin Solution.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether adding gemcitabine to BCG helps treat recurrent non‑muscle invasive bladder cancer.
- Who it's for
- You may be able to join if you have bladder cancer that has come back after BCG treatment.
- What's involved
- You will receive a chemotherapy drug called gemcitabine together with BCG, which is put into your bladder through a catheter. The treatment aims to kill cancer cells by using both drugs.
- Time commitment
- The study lasts several months and includes multiple visits for bladder treatments and follow‑up check‑ins.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Documentation of Disease: Histologic confirmation of urothelial carcinoma that is high grade Ta, high grade T1, or Tis (Tis/carcinoma in situ [CIS]...
- Any component of neuroendocrine carcinoma (i.e., small cell or large cell) is not allowed.
- All visible papillary lesions must be macroscopically resected by TURBT within 90 days of randomization. (Residual CIS is permitted).
- All patients with high grade T1 must undergo a restaging TURBT within 90 days of randomization.
- Patients must have BCG-Exposed non muscle invasive bladder carcinoma (NMIBC), defined as recurrent high grade NMIBC within 24 months of last BCG...
See the full eligibility criteria
- Documentation of Disease: Histologic confirmation of urothelial carcinoma that is high grade Ta, high grade T1, or Tis (Tis/carcinoma in situ [CIS] only disease) within 120 days prior to randomization
- Any component of neuroendocrine carcinoma (i.e., small cell or large cell) is not allowed. Other histologic subtypes/variant histologies are allowed so long as there is a predominantly urothelial component.
- All visible papillary lesions must be macroscopically resected by TURBT within 90 days of randomization. (Residual CIS is permitted).
- All patients with high grade T1 must undergo a restaging TURBT within 90 days of randomization. Patients who undergo a restaging TURBT that shows no residual cancer in the specimen are still eligible for trial based on...
- Patients must have BCG-Exposed non muscle invasive bladder carcinoma (NMIBC), defined as recurrent high grade NMIBC within 24 months of last BCG exposure but not meeting the definition of BCG unresponsive disease
- Note: Up to 26 months from the last BCG instillation is allowed for the treating physician to perform a transurethral resection of bladder tumor (TURBT) so long as there is evidence/suspicion of recurrent disease (by...
- Note: A patient who previously met the definition of BCG unresponsive NMIBC but no longer currently meets unresponsive criteria may still enroll in this trial so long as the treating urologist believes re-treatment with...
- Any high grade NMIBC recurrence within 24 months of induction only BCG, or
- A high grade papillary NMIBC (Ta/T1) recurrence between 6-24 months of last exposure to induction + maintenance BCG, or
- A high-grade CIS (with or without Ta/T1 papillary disease) recurrence within 12-24 months of last exposure to induction + maintenance BCG.
- Persistent or recurrent high-grade papillary NMIBC (Ta/T1) \< 6 months of "adequate" BCG, or
- A high-grade CIS (with or without Ta/T1 papillary disease) recurrence \< 12 months of "adequate" BCG, or
- A high grade T1 recurrence at the first 3-month assessment from induction BCG
- "Adequate" BCG is defined as ≥5 of 6 doses of induction BCG therapy with either
- ≥ 2 of 3 doses of maintenance BCG, or
- ≥ 2 of planned 6 instillations of repeat induction BCG given within a 6 month time period
- More than one prior induction course of BCG and/or prior maintenance BCG is allowed so long as the patient does not currently met the definition of BCG unresponsive disease
- Prior treatment with any intravesical chemotherapy (both perioperative and induction course) for NMIBC is allowed, including gemcitabine either alone or in combination (ie.
- Prior treatment with any systemic or intravesical agents for NMIBC is allowed, regardless of whether it is given either alone or in prior combination with BCG (ie.
- Patients must not have a history of intolerance to BCG (ie needing to stop BCG induction or maintenance due to toxicity) or intolerance to any other intravesical therapies
- Patients must not have compromised bladder function such that they are unlikely to tolerate further intravesical therapies
- Patient must not have any prior history or current evidence of muscle-invasive (i.e., T2, T3, T4), locally advanced unresectable, or metastatic urothelial carcinoma as assessed on radiographic imaging obtained within...
- Patients with a history of upper tract urothelial carcinoma are allowed so long as they had localized non-muscle invasive (Ta, T1, Tis) that has been definitively treated with surgery (nephroureterectomy or...
- Patients with a history of, or current evidence of, non-invasive (Ta/Tis) urothelial carcinoma of the prostatic urethra are eligible so long as a transurethral resection of prostate (TURP) is performed before enrollment...
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- Age ≥ 18 years
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or how well it works assessment of the investigational regimen are eligible for...
- has achieved menarche at some point
- has not undergone a hysterectomy or bilateral oophorectomy
- has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive...
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Fairbanks, Alaska, United States
- Gilbert, Arizona, United States
- Phoenix, Arizona, United States
- Irvine, California, United States
- Orange, California, United States
- Washington D.C., District of Columbia, United States
- Gainesville, Florida, United States
- Jacksonville, Florida, United States
- Coeur d'Alene, Idaho, United States
- Post Falls, Idaho, United States
- Sandpoint, Idaho, United States
- Chicago, Illinois, United States
- Maywood, Illinois, United States
- Melrose Park, Illinois, United States
- Avon, Indiana, United States
- Carmel, Indiana, United States
- Indianapolis, Indiana, United States
- Metairie, Louisiana, United States
- Baltimore, Maryland, United States
+ 35 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Fairbanks, Alaska, United States; Gilbert, Arizona, United States; Phoenix, Arizona, United States; Irvine, California, United States; Orange, California, United States and 49 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.